Thromb Haemost 2001; 86(05): 1136-1138
DOI: 10.1055/s-0037-1615979
Commentary
Schattauer GmbH

Genetic Polymorphisms to Evaluate the Risk of Myocardial Infarction: a Long Way away

Piera Angelica Merlini
1   IV Division of Cardiology, Ospedale Niguarda Milano, Parma, Italy
,
Diego Ardissino
1   Ospedale Maggiore di Parma, Universitá degli Studi di Parma, Parma, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2017 (online)

 

 
  • References

  • 1 Folsom AR. Hemostatic risk factors for atherothrombotic disease. Thromb Haemost 2001; 86: 1-7.
  • 2 Behague I, Poirier O, Nícaud V, Evans A, Arveiler D, Luc G, Cambou J-P, Scarabin P-Y, Bara L, Green F, Cambien F. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM study. Circulation 1996; 93: 440-9.
  • 3 Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen B 448 polymorphism, fibrinogen levels, and acute coronary disease. Arterioscler Thromb Vasc Biol 1997; 17: 589-94.
  • 4 Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutatÌon (G-455→A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on The Copenhagen City Heart Study. J Clin Invest 1997; 99: 3034-9.
  • 5 Gardemann A, Schwartz O, Haberbosch W, Katz N, Weiss T, Tillmanns H, Hehrlein FW, Waas W, Eberbach A. Positive association of the β-fibrinogen H1/H2 gene variation to basal fibrinogen levels and to increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost 1997; 77: 1120-6.
  • 6 Iacoviello L, Di Castelnuovo A, de Knijff P, D’Orazio A, Amore C, Arboretti R, Kluft C, Donati MB. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
  • 7 Moor E, Silveira A, van’t Hooft F, Suontaka AM, Eriksson P, Blomback M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
  • 8 Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambien F. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-27.
  • 9 Doggen CJM, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.
  • 10 Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinen L, Palomäki H, Kaste M. Arg506GIn factor V mutation in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-60.
  • 11 Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K. Evidence against heterozygous coagulation factor V 1691 GA mutation for coronary artery disease and myocardial infarction. J Molec Med 1995; 73: 521-4.
  • 12 Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, Tracy RP. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998; 79: 912-5.
  • 13 Dunn ST, Roberts CR, Schecter E, Moore WE, Lee ET, Eichner JE. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. Thromb Res 1998; 91: 91-9.
  • 14 Gardemann A, Arsic T, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The factor II G20210A and factor VG1691A gene transitions and coronary heart disease. Thromb Haemost 1999; 81: 208-13.
  • 15 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
  • 16 Van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1995; 1: 185-7.
  • 17 Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrarío M, Corral J, Margaglione M. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
  • 18 Vargas M, Soto I, Pinto CR, Urgelles MF, Batalla A, Rodriquez-Reguero J, Cortina A, Alvarez V, Coto E. The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coagul Fibrinol 1999; 10: 39-41.
  • 19 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth Jr WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
  • 20 Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-1041.
  • 21 Corral J, Gonzalez-Conejero R, Lozano ML, River J, Heras I, Vicente V. The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 1997; 99: 304-7.
  • 22 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-9.
  • 23 Eikelboom JW, Baker RI, Parsons R, Taylor RR, van Bockxmeer FM. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost 1998; 80: 878-80.
  • 24 Croft SA, Daly ME, Steeds RP, Channer KS, Samani NJ, Hampton KK. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost 1999; 81: 861-4.
  • 25 Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
  • 26 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Glodschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
  • 27 Mikkelsson J, Perola M, Laippala P, Savolainen V, Pajarinen J, Lalu Kaisa, Penttilä A, Karhunen PJ. Glycoprotein IIla PlA polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999; 19: 2573-8.
  • 28 Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl A polymorphism of glycoprotein IIb/IIIa and the fibrinogen β448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96: 1424-31.
  • 29 Zotz RB, Winkelmann BR, Nauck M, Giers G, Maruhn-Debowski B, März W, Scharf RE. Polymorphism of platelet membrane glycoprotein IIIa: Human platelet antigen Ib (HPA-1b/PI A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998; 79: 731-5.
  • 30 Gardemann A, Humme J, Stricker J, Nguyen QD, Katz N, Philipp M, Tillmanns H, Hehrlein FW, Rau M, Haberbosch W. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost 1998; 80: 214-8.
  • 31 Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffry S, Kaski JC, Cumberland DC, Duff GW, Crossman DC. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999; 99: 861-6.
  • 32 Zee RYL, Lunze K, Lindpaintner K, Ridker PM. A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost 2001; 86 (Suppl. 05) 1141-3.